|
Feb 12
|
New Strong Sell Stocks for February 12th
|
|
Jan 16
|
Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know
|
|
Jan 10
|
Prothena's (PRTA) Update on Pipeline Progress Disappoints
|
|
Jan 10
|
5 questions facing pharma in 2024
|
|
Jan 9
|
Here's Why Bristol Myers Squibb (BMY) Fell More Than Broader Market
|
|
Jan 2
|
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
|
|
Dec 29
|
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
|
|
Dec 29
|
Is Bristol-Myers Squibb Company (NYSE:BMY) A High Quality Stock To Own?
|
|
Dec 28
|
Bristol Myers Squibb (BMY) Rises Yet Lags Behind Market: Some Facts Worth Knowing
|
|
Dec 28
|
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals
|
|
Dec 28
|
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
|
|
Dec 28
|
Top 15 Value Stocks to Buy for 2024
|
|
Dec 28
|
11 Hot Healthcare Stocks To Buy Now
|
|
Dec 27
|
Cytokinetics Stock Skyrockets on Positive Results from Study of Its Heart Drug
|
|
Dec 27
|
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
|
|
Dec 27
|
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B
|
|
Dec 27
|
A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
|
|
Dec 27
|
Trending tickers: Intel | Tencent | RayzeBio | Astrazeneca
|
|
Dec 26
|
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
|
|
Dec 26
|
S&P 500 Gains and Losses Today: Intel's $3.2 Billion Incentives Deal from Israel
|